

KEAP1 E3 Ligase-Mediated Downregulation of NF- κ B Signaling by Targeting IKK β

Dung-Fang Lee,^{1,2} Hsu-Ping Kuo,^{1,2,8} Mo Liu,^{1,2,8} Chao-Kai Chou,^{1,2,8} Weiya Xia,¹ Yi Du,^{1,2} Jia Shen,^{1,2} Chun-Te Chen,^{1,2} Longfei Huo,¹ Ming-Chuan Hsu,¹ Chia-Wei Li,¹ Qingqing Ding,¹ Tsai-Lien Liao,³ Chien-Chen Lai,^{4,5} Ann-Chi Lin,³ Ya-Hui Chang,³ Shih-Feng Tsai,³ Long-Yuan Li,^{6,7} and Mien-Chie Hung^{1,2,6,7,*}

¹Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA

²Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA

³Division of Molecular and Genomic Medicine, National Health Research Institutes, Zhunan, Miaoli County 350, Taiwan

⁴Graduate Institute of Chinese Medical Science, China Medical University, Taichung 404, Taiwan

⁵Institute of Molecular Biology, National Chung Hsing University, Taichung 402, Taiwan

⁶Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital, Taichung 404, Taiwan

⁷Asia University, Taichung 413, Taiwan

⁸These authors contributed equally to this work

*Correspondence: mhung@mdanderson.org

DOI 10.1016/j.molcel.2009.07.025

SUMMARY

IKK β kinase β (IKK β) is involved in tumor development and progression through activation of the nuclear factor (NF)- κ B pathway. However, the molecular mechanism that regulates IKK β degradation remains largely unknown. Here, we show that a Cullin 3 (CUL3)-based ubiquitin ligase, Kelch-like ECH-associated protein 1 (KEAP1), is responsible for IKK β ubiquitination. Depletion of KEAP1 led to the accumulation and stabilization of IKK β and to upregulation of NF- κ B-derived tumor angiogenic factors. A systematic analysis of the *CUL3*, *KEAP1*, and *RBX1* genomic loci revealed a high percentage of genome loss and missense mutations in human cancers that failed to facilitate IKK β degradation. Our results suggest that the dysregulation of KEAP1-mediated IKK β ubiquitination may contribute to tumorigenesis.

INTRODUCTION

The ubiquitin-proteasome pathway is crucial for controlling the abundance of several proteins, and it plays an essential role in maintaining normal cellular functions. Kelch-like ECH-associated protein 1 (KEAP1) is a bric-a-brac (BTB)-Kelch protein that functions as a substrate adaptor protein for a Cullin 3 (CUL3)/Ring box 1 (RBX1)-dependent E3 ubiquitin ligase complex (Kobayashi et al., 2004; Zhang et al., 2004). The well-studied substrate for the KEAP1-CUL3 ubiquitin E3 ligase complex is nuclear factor erythroid-2-related factor 2 (NRF2) (Motohashi et al., 2004). The KEAP1-CUL3 ubiquitin E3 ligase complex interacts with and conjugates ubiquitin onto the N-terminal Neh2 domain of NRF2 and promotes NRF2 degradation through the 26S ubiquitin proteasome pathway (Itoh et al., 1999). While studying the role of the KEAP1-NRF2-signaling pathway in human cancers, it was noticed that several different kinds of KEAP1 somatic mutations were detected in both lung cancer

and gallbladder cancer (Ohta et al., 2008; Padmanabhan et al., 2006; Shibata et al., 2008; Singh et al., 2006). Moreover, loss of heterozygosity of KEAP1 genome regions (Singh et al., 2006) was frequently found in both lung cancer cell lines and lung cancer tissues. These genomic alternations result in constitutive NRF2 activation, which induces a couple of antioxidant-related enzymes to provide advantages of cancer cells for resistance to chemotherapeutic drugs (Shibata et al., 2008; Singh et al., 2006), implicating that KEAP1 might function as a tumor suppressor and loss of KEAP1 function confers tumorigenesis. Given that KEAP1 might function as a tumor suppressor protein to negatively regulate tumor progression and thus provide an advantage for chemotherapy, it is important to understand the KEAP1-involved signaling cascades.

IKK β kinase β (IKK β) functions as a fine-tuning controller of the nuclear factor (NF)- κ B pathway. NF- κ B activation governs the expression of myriad genes involved in the immune response, cell proliferation, angiogenesis, cell survival, tumor invasion, metastasis, and epithelial-mesenchymal transition (Karin and Greten, 2005; Perkins, 2007). In addition, IKK β has been shown to promote tumorigenicity through phosphorylation-mediated inhibition of tumor suppressors and thus is considered an oncogenic kinase (Hu et al., 2004; Lee and Hung, 2007; Lee et al., 2007). These findings strongly suggested that IKK β -mediated signaling cascades link inflammation to cancer pathogenesis.

In the current study, we demonstrate that KEAP1 functions as an IKK β E3 ubiquitin ligase. Depletion of KEAP1 led to the accumulation and stabilization of IKK β and upregulation of NF- κ B-derived tumor angiogenic factors. A systematic analysis of *CUL3*, *KEAP1*, and *RBX1* (E3 ubiquitin ligase complex) genomic loci revealed a high percentage of genome loss and missense mutations in human cancers that failed to facilitate IKK β degradation. Thus, our results suggest that inactivation of the KEAP1-CUL3-RBX1 complex in human cancers may prevent IKK β degradation and result in NF- κ B activation and that induction of KEAP1 expression may have vital clinical implications for the treatment or prevention of inflammation-associated cancers.




Figure 1. KEAP1 Selectively Inhibits the NF- κ B-Signaling Pathway

(A) Ectopic of KEAP1 suppressed TNF α -mediated RELA nuclear translocation. Hs578T breast cancer cells were transfected with either RFP-KEAP1 or vector, serum-starved overnight, treated with 2 ng/ml TNF α for 30 min, stained with anti-RELA antibodies (green), and examined by confocal microscopy. The nucleus was stained with DAPI (blue). The arrow indicates KEAP1-expressed cells (red).

(B) Depletion of endogenous KEAP1 by KEAP1 siRNA led to accumulation of nuclear RELA.

RESULTS AND DISCUSSION

KEAP1 Inhibits the NF- κ B-Signaling Pathway

Given that the genomic alternation of KEAP1 increases tumorigenicity and a number of NF- κ B downstream targets benefit the hallmark capabilities of multiple cancers, we sought to determine whether NF- κ B is involved in loss-of-KEAP1-induced tumor progression. To address this issue, we increased KEAP1 by ectopic expression or knocked down KEAP1 by siRNA to study the effects of each process on the NF- κ B-signaling pathway. Compared with vector control, ectopic expression of KEAP1 suppressed tumor necrosis factor (TNF) α -induced NF- κ B transcriptional activity as determined by a reporter assay (Figure S1A available online) and RELA nuclear translocation in cancer cells (from 90% to 36% in Hs578T cells and from 92% to 48% in MDA-MB-435 cells) (Figures 1A and S1B). Consistently, knockdown of KEAP1 increased nuclear location of RELA (Figures 1B and S2) and enhanced NF- κ B transcriptional activity (Figures 1C and S3A), but not SMAD transcriptional activity (Figure S3B). These results suggested that KEAP1 might specifically block the TNF α -NF- κ B-signaling pathway.

Furthermore, we explored the expression of a broad spectrum of NF- κ B-responsive genes in four breast cancer cell lines by using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Several NF- κ B-regulated genes, including IL-8, CCL2, BIRC3, and PLAU, were upregulated in multiple human breast cancer cell lines when KEAP1 was depleted, as shown in heat maps (Figure 1D and Table S1). Because IL-8 is a potent angiogenic factor, this result raises an interesting possibility that KEAP1 might inhibit tumor angiogenesis through the downregulation of IL-8. Indeed, *in vitro* angiogenesis assays revealed that siRNA-mediated inhibition of KEAP1 expression increased human umbilical vein endothelial cell (HUVEC) migration (Figure 1E) and tube formation (Figure 1F). Neutralizing IL-8 by using anti-IL-8 antibodies repressed the HUVEC migration and tube formation induced by KEAP1 siRNA knockdown cells to a level similar to that induced by control cells (Figures 1E and 1F).

NRF2 transcription factor is a major target degraded by KEAP1, so we questioned whether KEAP1-mediated downregulation of IL-8 expression might be related to NRF2. However, this possibility was ruled out because silencing NRF2 had no effect on IL-8 mRNA or on protein expression induced by KEAP1 knockdown, as determined by qRT-PCR and an enzyme-linked immunosorbent assay (ELISA), respectively (Figures 1G and 1H). Together, these results suggest that KEAP1 downregulates IKK β and suppresses NF- κ B-mediated IL-8 expression, which culminates in inhibition of *in vitro* angiogenesis.

KEAP1 Directly Interacts with IKK β

These observations raised an intriguing question of how KEAP1 negatively modulates the NF- κ B signaling. Because KEAP1 is an E3 ubiquitin ligase, we hypothesized that KEAP1 suppresses NF- κ B activity through downregulation of an essential component in the TNF α -NF- κ B signaling pathway. siRNA-mediated knockdown of KEAP1 caused a significant increase in the amount of IKK β but did not alter the amounts of other related molecules, which have been suggested to be required for NF- κ B activation (Figure 2A). KEAP1-mediated IKK β downregulation was rescued by MG132 (Figure S4), suggesting that KEAP1 mediates IKK β degradation via the ubiquitin proteasome process. To investigate whether IKK β is required for KEAP1-regulated NF- κ B activity, we examined the effect of KEAP1 knockdown on IKK β -depleted cells, and the result showed that silencing KEAP1 does not upregulate NF- κ B activity (Figure S5), which further supports the notion that KEAP1 represses NF- κ B function by inducing IKK β degradation.

Furthermore, coimmunoprecipitation assays demonstrated that IKK β physically interacted with KEAP1 *in vivo* (Figure 2B). This interaction was also observed with endogenous IKK β and KEAP1 when specific antibodies to IKK β were used (Figure 2C). An *in vitro* pull-down assay further suggested a direct association between IKK β and KEAP1 (Figure 2D). In addition, the endogenous binding between KEAP1 and IKK β was not affected by TNF α (Figure 2C), and an increase in IKK β by KEAP1 depletion did not change after TNF α treatment (Figure 2E), indicating that the regulation of IKK β by KEAP1 is independent of IKK β activity. To define the region of KEAP1 required for IKK β interaction, we used coimmunoprecipitation and mammalian two-hybrid assays to examine the binding abilities of different KEAP1 domain truncation mutants to IKK β . We found that IKK β strongly interacted with the Kelch domain of KEAP1 (Figures 2F and 2G). To further examine whether other cancer-related E3 ligases (SMURF2, MDM2, and SKP2) or Kelch domain-containing proteins (ND1L, GIGAXONIN, and ACTINFI-LIN) could also interact with IKK β , we performed coimmunoprecipitation assays and found that these well-characterized E3 ligases were unable to coimmunoprecipitate with IKK β , indicating that the interaction between KEAP1 and IKK β is specific (Figures S6A and S6B).

KEAP1 Functions as a CUL3-Based E3 Ligase of IKK β

Given that depletion of KEAP1 leads to IKK β accumulation and that the Kelch domain is required for KEAP1 substrate recognition and binding, we further investigated whether IKK β is a physical substrate of KEAP1. Ectopic expression of KEAP1 resulted in polyubiquitination of IKK β in the presence of wild-type, but not

(C) Knockdown of KEAP1 increased TNF α -induced NF- κ B activation. The 5 κ B-Luc reporter and TK-rLuc (internal control) were transfected with either KEAP1 siRNA or control siRNA into MDA-MB-435 cells. Then, 48 hr posttransfection, cells were serum starved overnight and treated with 2 ng/ml TNF α . After 8 hr of TNF α treatment, cells were recovered in 1% serum medium overnight and then lysed for luciferase assays. Error bars represent SD; n = 3.

(D) Silencing KEAP1 by KEAP1 siRNA upregulated the expression of NF- κ B-responsive genes in human breast cancer cells. A heat map depicts the relative expression of 12 NF- κ B-dependent genes by qRT-PCR. A nonspecific siRNA was used as the control.

(E and F) *In vitro* angiogenesis assays showed that the silencing of KEAP1 increases HUVEC tube formation and migration in comparison with the control. Depletion of IL-8 by antibodies to IL-8 (α -IL-8) suppressed knockdown of KEAP1-induced HUVEC migration and tube formation. Error bars represent SD; n = 3.

(G and H) Depletion of KEAP1 following TNF α stimulation increased IL-8 mRNA and protein levels as determined by qRT-PCR and ELISA, respectively. Knockdown of NRF2 had no effects on KEAP1 depletion-induced IL-8 expression. Error bars represent SD; n = 3.




Figure 2. KEAP1 Interacts with IKK β via KEAP1 Kelch Domain

(A) Depletion of endogenous KEAP1 by KEAP1 siRNA led to accumulation of IKK β , but not of other components involved in NF- κ B activation. (B) Exogenous interaction between KEAP1 and IKK β . Lysates of HEK293T cells cotransfected with HA-tagged KEAP1 and Flag-tagged IKK β . (C) Endogenous interaction between KEAP1 and IKK β in both unstimulated and TNF α -stimulated MDA-MB-435 and HEK293 cells.

K48R, ubiquitin (Figure 3A), which suggests that KEAP1-mediated IKK β ubiquitination is K48-type polyubiquitination. Consistent with the interaction results (Figure S6A), KEAP1 was much more efficient than other BTB/Kelch domain proteins were in promoting IKK β ubiquitination (Figure S7). Depletion of KEAP1 decreased endogenous IKK β ubiquitination (Figure S8A), and the IKK β ubiquitination status was not altered under TNF α stimulation (Figure S8B), indicating that KEAP1-mediated IKK β ubiquitination is independent of IKK β activity. Because KEAP1 functions as an adaptor to recruit its substrates into a CUL3-based ubiquitin ligase complex, we attempted to determine whether IKK β is associated with and ubiquitinated by the KEAP1-CUL3-RBX1 complex. In CUL3 immunoprecipitates, the IKK β level was markedly increased in the presence of coexpressed KEAP1 (Figure 3B), which is in agreement with the notion that KEAP1 functions as a bridge for IKK β and CUL3-RBX1 complex. Additionally, coexpression of CUL3 and RBX1 facilitated KEAP1-mediated IKK β ubiquitination (Figure S9), indicating that CUL3 and RBX1 are involved in KEAP1-derived ubiquitin conjugation onto IKK β . Consistently, we reconstituted the ubiquitination of IKK β in vitro and showed that IKK β was efficiently ubiquitinated when KEAP1, CUL3, and RBX1 all participated in the reaction (Figure 3C). No IKK β ubiquitination was found when the reaction mixture lacked the E1 ubiquitin-activating enzyme, supporting the evidence that IKK β ubiquitination occurred in vitro.

It has been shown that KEAP1's substrates have a (D/N)XE(T/S)GE motif that is required for KEAP1 binding (Kobayashi et al., 2004; Lo and Hannink, 2006). We noticed that IKK β also contains this motif (NQE³⁶TGE³⁹) at its kinase domain (Figure 3D). Compared with the IKK β wild-type, IKK β mutants (E36A and E39A) were resistant to downregulation by KEAP1 (Figure 3E). Consistently, the IKK β ETGE motif mutants had decreased ability to bind to KEAP1 (Figure 3F) and were resistant to KEAP1-mediated ubiquitination (Figure 3G). We further applied mass spectrometric analysis to identify the ubiquitination site in IKK β and found that K555 is the site of KEAP1-mediated IKK β ubiquitination (Figure 3H). These results suggest that the KEAP1-CUL3-RBX1 ubiquitin proteasome complex is responsible for ubiquitin-mediated proteolysis of the IKK β and IKK β ETGE motifs and is essential for KEAP1 recognition and binding.

Of interest, this motif exists only in human, chimpanzee, and dog and not in rat and mouse, suggesting that Keap1/IKK β regulation may not exist in the rodent cells. To support this notion, we examined whether Keap1 negatively regulates IKK β in mouse cells. We found that knockdown of Keap1 did not affect endogenous IKK β expression in mouse mammary tumor 4T1 cells (Figure S10A). In addition, mouse Keap1 did not associate with IKK β wild-type and E39A mutant or induce IKK β ubiquitination (Figures S10B and S10C). Taken together, our data suggest

that KEAP1-mediated IKK β ubiquitination and downregulation may be specific to advanced mammals.

Genomic Losses of KEAP1, CUL3, and RBX1 Loci in Human Cancers







In the early stages of cancer development, the loss of genomic stability is considered an imperative molecular and genetic step toward providing a permissive environment for the occurrence of alterations in oncogenes and tumor suppressor genes. Progressive accumulation of genetic and epigenetic alterations leads to the transformation of normal cells into malignant tumors. Using comparative genomic approaches, we investigated whether the KEAP1-CUL3-RBX1- $\text{IKK}\beta$ axis is dysregulated in human breast, esophageal, and liver cancers, which generally show abnormal upregulation of NF- κ B activity. In 42 breast cancer cell lines, an evaluation using single-nucleotide polymorphism (SNP) arrays of copy numbers at the *CUL3* (between rs2216460 and rs1368884), *KEAP1* (between rs2112527 and rs726789), and *RBX1* (between rs4266112 and rs139480) loci revealed that recurrent copy number loss involving both the upstream and downstream regions of the *CUL3* (25 of 42), *KEAP1* (10 of 42), and *RBX1* (23 of 42) loci was frequent in breast cancer cell lines (Figure 4A). The average amount of copy number loss was greater at the *CUL3* (0.85 for rs2216460 and 0.86 for rs1368884) and *RBX1* (0.83 for rs426612 and 0.92 for rs139480) loci than at the *KEAP1* locus (1.08 for rs2112527 and 0.98 for rs726789), implying that genomic losses of *CUL3* and *RBX1* might lead to upregulated NF- κ B signaling through dysregulation of the IKK β ubiquitin proteolysis mechanism in breast cancers. In addition, British Columbia Cancer Research Center (BCCRC) submegabase resolution tiling (SMRT) arrays of 17 breast cancer cell lines analyzed by using System for Integrative Genomic Microarray Analysis (SIGMA) software (Chari et al., 2006) supported the notion that allelic loss of the *CUL3* and *RBX1* loci occurs in breast cancer (Figure 4B). Similarly, regular copy number loss of the *KEAP1* (0.85 for rs426612 and 0.90 for rs139480 in nine liver cancer cell lines; Figure S11A) and *CUL3* (0.71 for rs2216460 and 0.80 for rs1368884 in 28 esophageal cancer cell lines; Figure S11B) loci occurred. High percentages of genome copy number variations were found in liver, colorectal, and lung cancer tissues, but almost no variations were found in their adjacent normal tissues (Table S2), indicating that genome alternation at the *CUL3*, *KEAP1*, and *RBX1* loci might contribute to several types of cancer development. In summary, these genomic studies found that different rates of loss at the *CUL3*, *KEAP1*, and *RBX1* loci occur in multiple human cancers, which results in an incomplete KEAP1-CUL3-RBX1 ubiquitin proteasome complex and may culminate in NF- κ B activation through impairment of IKK β degradation.

(D) KEAP1 directly interacted with IKK β . In vitro transcribed and translated [35S]-methionine-labeled KEAP1 proteins were incubated with recombinant His-tagged IKK β proteins, pulled down by Ni²⁺ beads, separated by SDS-PAGE, and visualized by autoradiography. IVT, in vitro transcription and translation.

(E) The effect of KEAP1 knockdown on TNF α -mediated IKK β activation.

(F) Interaction between the KEAP1 Kelch domain and IKK β as examined by co-IP. Schematic shows five different domains of KEAP1, including an N-terminal region (amino acids 1–60), a BTB domain (amino acids 61–179), a BACK domain (amino acids 180–314), a Kelch domain (amino acids 315–598, six Kelch motifs), and a C-terminal domain (amino acids 599–624).

(G) Mammalian two-hybrid assay revealed the direct interaction between KEAP1 Kelch domain and IKK β . The indicated regions of KEAP1 fused to the GAL4 DNA-binding domain (DBD) were cotransfected VP16 activation domain (AD)-fused IKK β (full-length), GAL4 luciferase reporter, and TK-rLuc reporter (internal control). Error bars represent SD; n = 3.



Clinical Association between IKK β Expression, KEAP1 and CUL3 Expression, and Survival in Breast Cancer Patients

To justify the pathological relevance of the relationship between IKK β and the KEAP1-CUL3-RBX1 ubiquitin complex, we analyzed IKK β , KEAP1, and CUL3 protein expression in 119 human breast cancer specimens by using immunohistochemical (IHC) staining. After hierarchical clustering, the results showed that negative IKK β expression was detected in 26 (66.7%) of 39 specimens with high KEAP1/CUL3 expression and that IKK β expression was inversely correlated with KEAP1/CUL3 expression ($p < 0.034$; Figure 4C and Table S3). This correlation was also observed between the KEAP1/CUL3 complex and NRF2 ($p < 0.007$; Table S4). Figure 4D shows the representative IHC-stained tumor specimens from consecutive sections in two patients, demonstrating the inverse correlation between IKK β expression and KEAP1/CUL3 expression.

We next analyzed KEAP1 and CUL3 expression in breast tumor tissues and correlated the findings with patient survival data. The Kaplan-Meier overall survival curves showed that low KEAP1 levels were associated with poor survival ($p < 0.014$; Figure S12). Moreover, the combination of low KEAP1/CUL3 expression and high IKK β expression was a better predictor of survival than either factor alone was ($p < 0.006$ versus $p < 0.006$; Figure 4E). Consistently, cDNA microarray data from 286 lymph node-negative patients (Wang et al., 2005), identified in the Integrated Tumor Transcriptome Array and Clinical Data Analysis database (Elfilali et al., 2006), showed that KEAP1 expression in breast cancer patients with a relapse-free survival duration of at least 5 years was higher than that in patients with a relapse-free survival of less than 5 years (Figure S13). Taken together, the tumor IHC staining data and cDNA microarray data further strengthened the notion that the KEAP1-CUL3-RBX1 ubiquitin complex promotes oncogenic kinase IKK β degradation and that downregulation of KEAP1 and/or CUL3 expression is associated with poor clinical outcome in patients with breast cancer.

Human Cancer Somatic Mutations Significantly Reduced KEAP1-Mediated IKK β Ubiquitination

To further determine whether deficient functioning of the KEAP1 mutation may negate its ability to degrade IKK β in human cancers, we sequenced KEAP1 protein-coding exons (E2–E6)

in a set of 26 cancer cell lines (18 from breast, 4 from liver, and 4 from lung) and 119 primary tumors (17 from breast, 78 from liver, 13 from lung, and 11 from colon). One additional SNP (G9R) and three nonsynonymous somatic mutations (H274L, S404X, and D479G) were identified in the liver cancer specimens (Figure S14 and Table S5). We then investigated the functional effects of these KEAP1 mutations and found that the S404X and D479G mutants, but not the G9R and H274L mutants, exhibited reduced IKK β binding potential compared with wild-type KEAP1 and thus were unable to promote IKK β ubiquitination (Figure 4F). Consistently, S404X and D479G mutants were not able to regulate NRF2 ubiquitination and degradation (Figures S15A and S15B). To further validate these cancer-associated mutations with regard to NF- κ B activation, we knocked down endogenous KEAP1 by KEAP1 siRNA targeting the KEAP1 mRNA 3' untranslated region (UTR), re-expressing the KEAP1 wild-type and mutants into cells, and studying their effects on NF- κ B pathway by examining a panel of NF- κ B-targeted mRNA expressions by qRT-PCR. The results showed that wild-type KEAP1 decreased several NF- κ B-targeted mRNA expressions in comparison to vector control and that S404X and D479G mutants function as dominant-negative forms, as shown by the significant increase in NF- κ B downstream gene expression via re-expressing these mutants (Figure 4G). These data suggest that cancer-associated mutations fail to facilitate IKK β degradation and further contribute to cancer development via the upregulation of NF- κ B activity.

Moreover, several KEAP1 mutants have recently been identified in lung and breast cancers (Ohta et al., 2008; Padmanabhan et al., 2006; Singh et al., 2006; Wood et al., 2007). Some mutations on the N-terminal and BTB domains of KEAP1 were found to interfere with the KEAP1-CUL3-RBX1 ubiquitin complex formation, and other mutations on Kelch domains were found to reduce KEAP1 binding affinity for NRF2, which results in stabilizing NRF (Nioi and Nguyen, 2007; Ohta et al., 2008; Padmanabhan et al., 2006; Singh et al., 2006). We sought to determine whether these previously identified KEAP1 mutants (C23Y, G333C, G364C, R413L, and G430C) were unable to catalyze IKK β ubiquitination. We found that four of the five KEAP1 mutants (G333C, G364C, R413L, and G430C) were not able to associate with and trigger IKK β ubiquitination (Figure S16), which was consistent with the results for decreased E3 ligase activity on NRF2 (Padmanabhan et al., 2006; Singh et al.,

Figure 3. KEAP1 Functions as a CUL3-Based E3 Ligase of IKK β

(A) KEAP1-dependent K48 ubiquitination of IKK β in vivo. Flag-tagged IKK β and HA-tagged KEAP1 were cotransfected with either wild-type or K48R mutant ubiquitin into HEK293T cells. After 24 hr posttransfection, cells were treated with MG132 for 6 hr. Flag-tagged IKK β was immunoprecipitated, and then ubiquitination was analyzed by blotting with anti-ubiquitin antibody.

(B) KEAP1 bridges the interaction between IKK β and the CUL3-RBX1 complex. CUL3 immunoprecipitates were analyzed by immunoblot with the indicated antibodies.


(C) In vitro ubiquitination of IKK β by the KEAP1-CUL3-RBX1 complex. Flag-tagged IKK β was incubated with KEAP1, CUL3, and RBX1 in the presence of E1, E2, His-Ubiquitin, and ATP as indicated.

(D) Human IKK β contains a KEAP1-binding (D/N)X(E/T/S)GE motif (D, aspartic acid; N, asparagine; E, glutamic acid; T, threonine; S, serine; G, glycine; and X, any amino acid).

(E) KEAP1 markedly decreased steady-state levels of wild-type, but not E36A and E39A mutant, IKK β . GFP served as an internal control.

(F and G) E36A and E39A mutant IKK β markedly reduced their binding ability to KEAP1 and were resistant to KEAP1-mediated ubiquitination.

(H) Mass spectrometry analysis revealed that IKK β K555 is a polyubiquitination site. Flag-tagged IKK β , HA-tagged KEAP1, and HA-tagged ubiquitin were cotransfected into HEK293T cells. After 1 day posttransfection, cells were treated with MG132 for 6 hr to prevent the degradation of polyubiquitinated IKK β . Polyubiquitinated IKK β were pulled down by using antibodies against HA tags and were analyzed by μ -LC/MS/MS mass spectrometry.



2006). However, there was no difference between wild-type KEAP1 and C23Y mutant-mediated IKK β ubiquitination. It is worthwhile to mention that these six functionally deficient KEAP1 mutants (G333C, G364C, S404X, R413L, G430C, and D479G) are all mutated in the Kelch domain (amino acids 315–598, the IKK β interaction region), which is consistent with our finding of the importance of the KEAP1 Kelch domain for IKK β binding (Figures 2F and 2G). Taken together, these results suggest a possibility that allelic loss of the *KEAP1*, *CUL3*, and *RBX1* genes and/or missense mutations on *KEAP1* may increase IKK β stability, which then results in activation of the NF- κ B pathway in human cancers.

We also investigated whether mutations exist in the IKK β NQETGE region, which might prevent binding to KEAP1 and result in increased IKK β expression, but we did not find any somatic mutations in this region in a set of 119 primary tumors (17 from breast, 78 from liver, 13 from lung, and 11 from colon) and 26 cancer cell lines (18 from breast, 4 from liver, and 4 from lung) (data not shown). Recently, a cancer-derived IKK β mutant (A360S) was identified in a human breast cancer cell line (Wood et al., 2007). We examined whether this mutation is resistant to KEAP1-mediated ubiquitination and found that the breast cancer-derived IKK β A360S mutant could still be ubiquitinated by KEAP1 (Figure S17), suggesting that dysregulation of KEAP1-mediated IKK β degradation might result primarily from low activity of the KEAP1-CUL3-RBX1 ubiquitin complex (as a result of somatic mutations or allelic loss), but not from somatic *IKK β* mutations. In summary, the loss of KEAP1-CUL3-RBX1 function is a frequent event in human cancers that prevents IKK β from degrading, leading to activation of that NF- κ B pathway and angiogenesis.

In summary, we discovered that KEAP1 downregulates the NF- κ B-signaling pathway by functioning as an IKK β E3 ligase (Figure S18). Our study links cancer genomic alternations and the aberrant activation of oncogenic signaling pathways and suggests that ubiquitin-mediated oncoprotein proteolysis contributes to inflammation-associated tumor development. Given that the induction of KEAP1 expression will kill two birds (IKK β and NRF2) with one stone (KEAP1), further investigations to identify the KEAP1 activation mechanism and development of drugs targeting KEAP1 expression may have vital clinical implications for the treatment or prevention of cancers.

EXPERIMENTAL PROCEDURES

Quantitative RT-PCR

We extracted total RNA from the cells by using TRIzol (Invitrogen) and quantified the total RNA by using the SmartSpec Plus Spectrophotometer (BIORAD). We performed reverse transcription using the Superscript III first-stand synthesis system (Invitrogen) according to the manufacturer's instructions. We performed qRT-PCR analyses of human *BIRC4*, *PTGS2*, *NFKBIA*, *PLAU*, *BIRC3*, *IL-8*, *GADD45B*, *SOD2*, *CCND1*, *CCL2*, *IL-1A*, *BCL2L1*, and *KEAP1* by using designed primers (Table S6) and iQ SYBR Green Supermix (BIORAD). We then performed assays by using the ABI StepOne Plus Real-Time PCR system (Applied Biosystems). We used *GAPDH* for normalization.

Genome Structure Analyses

For SNP-based copy number analysis, we obtained Affymetrix 10K SNP microarray genotype data for 42 breast cancer cell lines, 9 liver cancer cell lines, and 27 esophageal cancer cell lines from the Cancer Genome Project of the Wellcome Trust Sanger Institute. We analyzed the SNP data of the *CUL3*, *KEAP1*, and *RBX1* loci; visualized them by using the Cluster and TreeView software (Eisen, MB); and presented the results by using heat maps. For array comparative genomic hybridization (aCGH) analysis, we used SIGMA software (Chari et al., 2006) to examine the genomic gain and loss of the *CUL3*, *KEAP1*, and *RBX1* loci and obtained results from BCCRC SMRT arrays of 17 breast cancer cell lines with genome karyograms using the March 2006 genomic build.

SUPPLEMENTAL DATA

Supplemental Data include Supplemental Experimental Procedures, 18 figures, and 7 tables and can be found with this article online at [http://www.cell.com/molecular-cell/supplemental/S1097-2765\(09\)00580-2](http://www.cell.com/molecular-cell/supplemental/S1097-2765(09)00580-2).

ACKNOWLEDGMENTS

We thank Drs. B. Chen, R.B. Gaynor, M. Hatano, M. Li, Y. Xiong, M. Yamamoto, and Y. Yang for providing reagents; Drs. R. Zhao and Y.-L. Lin for technical support; S. Sen of the DNA Analysis Core Facility at The University of Texas M.D. Anderson Cancer Center for fluorescent fragment analysis; and S.A. Miller, T. Locke, A. Todd, and V.M. Mohlere of the Department of Scientific Publications at The University of Texas M.D. Anderson Cancer Center for editorial assistance. This work was partially supported by the National Institutes of Health (grants R01 CA109311, PO1 CA099031, and CCSG CA16672), M.D. Anderson SPORE grants (P50 CA116199 for breast cancer, P20 CA101936 for pancreatic cancer, and P50 CA83639 for ovarian cancer), The Breast Cancer Research Foundation, Kadoorie Charitable Foundations, Patel Memorial Breast Cancer Endowment Fund, and National Breast Cancer Foundation Inc. to M.-C.H. It was also partially supported by a grant from Taiwan National Science Council (NSC-96-3111-B) to L.-Y.L. and M.-C.H.;

Figure 4. Negative Regulation of IKK β by KEAP1-CUL3-RBX1 Ubiquitin Complex Is Altered in Human Cancers

- (A) Analysis of the *CUL3*, *KEAP1*, and *RBX1* loci by 10 K SNP arrays in 42 breast cancer cell lines. Colograms represent SNP copy numbers. (Red) Allelic gain. (Green) Allelic loss.
- (B) SIGMA analysis of the *CUL3*, *KEAP1*, and *RBX1* loci based on aCGH data. (Red) Areas of recurrent gain. (Green) Areas of recurrent loss. The maximum values of 1 and -1 represent gain and loss of that area in all samples, respectively.
- (C) A reverse clinical correlation existed between IKK β , KEAP1, and CUL3 expression in 119 breast cancer specimens ($p < 0.039$). Hierarchical clustering was performed on the CLUSTER program and constructed using Treeview software to show a cohort of 119 breast cancer samples stained with IKK β , KEAP1, and CUL3 expressions, and the heat map representation of the data is shown. Detailed information is presented in Table S3.
- (D) IKK β expression levels were negatively associated with KEAP1 and CUL3 expression in 119 primary human breast cancer specimens. Shown are two representative specimens.
- (E) The Kaplan-Meier overall survival curves indicate that KEAP1 and CUL3 together are associated with an increase in overall survival in breast cancer patients.
- (F) In liver cancer, the KEAP1 Kelch domain mutants (S404X and D479G), but not the N domain mutant (G9R) or BACK domain mutant (H274L), have weaker binding abilities to IKK β and consequently were unable to catalyze IKK β ubiquitination.
- (G) Wild-type KEAP1 negatively downregulates NF- κ B activity, and KEAP1 Kelch domain mutants (S404X and D479G) serve as dominant-negative forms to regulate NF- κ B function. Endogenous KEAP1 was first knocked down by Accell KEAP1 siRNA, which targets the *KEAP1* mRNA 3' UTR region. The KEAP1 knocked-down MDA-MB-435 cells were further transfected with wild-type and mutant KEAP1, and a panel of NF- κ B-targeting gene expression was examined by qRT-PCR.

a grant from National Health Research Institutes (NHRI-EX98-9603BC) and a grant from Department of Health (DOH98-TD-I-111-TM002) to L.-Y.L.; a predoctoral fellowship from the U.S. Army Breast Cancer Research Program (grant W81XWH-05-1-0252), Presidents' Research Scholarship, T.C. Hsu Endowed Memorial Scholarship, and Andrew Sowell-Wade Huggins Scholarship from The University of Texas Graduate School of Biomedical Sciences at Houston to D.-F.L.; a predoctoral fellowship from the U.S. Army Breast Cancer Research Program (grant W81XWH-08-1-0397) and Andrew Sowell-Wade Huggins Scholarship from The University of Texas Graduate School of Biomedical Sciences at Houston to H.-P.K.; a predoctoral fellowship from the U.S. Army Breast Cancer Research Program (grant W81XWH-06-1-0709) to C.-K.C.; and a Research Assistant Scholarship from The University of Texas Graduate School of Biomedical Sciences at Houston to M.L. and J.S.

Received: January 5, 2009

Revised: June 1, 2009

Accepted: July 31, 2009

Published: October 8, 2009

REFERENCES

- Chari, R., Lockwood, W.W., Coe, B.P., Chu, A., Macey, D., Thomson, A., Davies, J.J., MacAulay, C., and Lam, W.L. (2006). SIGMA: a system for integrative genomic microarray analysis of cancer genomes. *BMC Genomics* 7, 324.
- Elfilali, A., Lair, S., Verbeke, C., La Rosa, P., Radvanyi, F., and Barillot, E. (2006). ITTACA: a new database for integrated tumor transcriptome array and clinical data analysis. *Nucleic Acids Res.* 34, D613–D616.
- Hu, M.C., Lee, D.F., Xia, W., Golfman, L.S., Ou-Yang, F., Yang, J.Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. (2004). I κ B kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. *Cell* 117, 225–237.
- Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J.D., and Yamamoto, M. (1999). Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev.* 13, 76–86.
- Karin, M., and Greten, F.R. (2005). NF- κ B: linking inflammation and immunity to cancer development and progression. *Nat. Rev. Immunol.* 5, 749–759.
- Kobayashi, A., Kang, M.I., Okawa, H., Ohtsui, M., Zenke, Y., Chiba, T., Igarashi, K., and Yamamoto, M. (2004). Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. *Mol. Cell. Biol.* 24, 7130–7139.
- Lee, D.F., and Hung, M.C. (2007). All roads lead to mTOR: integrating inflammation and tumor angiogenesis. *Cell Cycle* 6, 3011–3014.
- Lee, D.F., Kuo, H.P., Chen, C.T., Hsu, J.M., Chou, C.K., Wei, Y., Sun, H.L., Li, L.Y., Ping, B., Huang, W.C., et al. (2007). IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. *Cell* 130, 440–455.
- Lo, S.C., and Hannink, M. (2006). PGAM5, a Bcl-XL-interacting protein, is a novel substrate for the redox-regulated Keap1-dependent ubiquitin ligase complex. *J. Biol. Chem.* 281, 37893–37903.
- Motohashi, H., Katsuoka, F., Engel, J.D., and Yamamoto, M. (2004). Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. *Proc. Natl. Acad. Sci. USA* 101, 6379–6384.
- Nioi, P., and Nguyen, T. (2007). A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. *Biochem. Biophys. Res. Commun.* 362, 816–821.
- Ohta, T., Iijima, K., Miyamoto, M., Nakahara, I., Tanaka, H., Ohtsui, M., Suzuki, T., Kobayashi, A., Yokota, J., Sakiyama, T., et al. (2008). Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. *Cancer Res.* 68, 1303–1309.
- Padmanabhan, B., Tong, K.I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsui, M., Kang, M.I., Kobayashi, A., Yokoyama, S., and Yamamoto, M. (2006). Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. *Mol. Cell* 21, 689–700.
- Perkins, N.D. (2007). Integrating cell-signalling pathways with NF- κ B and IKK function. *Nat. Rev. Mol. Cell Biol.* 8, 49–62.
- Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., and Hirohashi, S. (2008). Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. *Gastroenterology* 135, 1358–1368.
- Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., Hoque, M.O., Herman, J.G., Baylin, S.B., Sidransky, D., Gabrielson, E., et al. (2006). Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. *PLoS Med.* 3, e420.
- Wang, Y., Klijn, J.G., Zhang, Y., Sieuwerts, A.M., Look, M.P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M.E., Yu, J., et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet* 365, 671–679.
- Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjoblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., et al. (2007). The genomic landscapes of human breast and colorectal cancers. *Science* 318, 1108–1113.
- Zhang, D.D., Lo, S.C., Cross, J.V., Templeton, D.J., and Hannink, M. (2004). Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. *Mol. Cell. Biol.* 24, 10941–10953.